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Some derivatives of the 4-arylsalicylketoximes series displayed inhibitory 
effects on glucose transport and on cell proliferation in several biological 
assays,[1] resulting to be effective GLUT1 inhibitors also in GLUT1-containing giant 
vesicles. GLUT1 is one of the 14 glucose transporter isoforms, widely 
overexpressed in many cancer types. Thus, for the discovered properties, the 
oximes of interest represent interesting candidates for anticancer therapy. 
Variously substituted 4-arylsalicylketoximes (3, Fig.1) were synthetized via 
Suzuki cross-coupling and a subsequent condensation of the resulting biaryl-
ketone intermediates with hydroxylamine hydrochloride. [1] Rat GLUT1 
membrane proteins were produced by Pichia Pastoris cultures, and purified 
following GLUT1 purification protocols, [2] which were largely revised to avoid the 
protein cleavage.  
Compounds 3a, 3b, 3e, and 3f efficiently inhibited glucose uptake in GLUT1-
containing giant vesicle assays. [3] To study the nature of the binding process 
between GLUT1 and the synthetic compounds, many crystallization attempts 
were set up with 3a and 3e using Lipidic Cubic Phase method, which produced 
many small crystals.  
Since many isoforms of GLUTs are overexpressed in cancer cells, inhibition of 
other GLUT isoforms, such as GLUT3, will be tested in the near future. 
In conclusion, 4-arylsalicylketoximes showed good inhibition of GLUT1 
isoform. First results from GLUT3-giant vesicles assays revealed that, within this 
series of compounds, 3a is the most selective GLUT1-inhibitor. Further assays 
with GLUTs-containing giant vesicle and crystallization attempts are currently 
underway.  
 
 
 
 
Figure 1: Generic structure of the salicylketoximes 3. 
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